SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

GameStop Corp. engages in offering games and entertainment products through its ecommerce properties and stores. The firm’s stores and ecommerce sites operate primarily under the names GameStop, EB Games, and Micromania. It operates through the following geographical segments: United States, Canada, Australia, and Europe. The company was founded by Daniel A. DeMatteo in 1996 and is headquartered in Grapevine, TX.

Gamestop Corporation - Ordinary Shares - Class A

GameStop Corp

GameStop is trending following a private exchange of $1.4 billion in convertible senior notes for common stock, a move that community members are debating as either a strategic balance sheet improvement or further dilutive pressure on shareholders. The conversation remains highly polarized, with active discussions focused on whether this debt-for-equity swap is a precursor to a potential acquisition, such as an eBay merger, or a sign of continued lack of value creation for retail investors.

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

TG Therapeutics is trending as investors react to the launch of a new Phase II study for Briumvi in treatment-resistant schizophrenia, further fueling speculation about its potential as a broad-based autoimmune franchise. The community remains focused on the company's strong revenue growth, persistent rumors of an acquisition, and frustration with analysts maintaining low price targets despite the stock's steady climb toward all-time highs.

Space Exploration Technologies Corp. (SpaceX) designs, manufactures, and launches advanced rockets and spacecraft, including the fully reusable Starship and Super Heavy rocket system, targeting missions to Earth orbit, the Moon, Mars, and beyond. The company is based in Hawthorne, CA and has subsidiaries in Luxembourg and the United States. The company operates Starlink, a low-Earth orbit satellite constellation that delivers high-speed broadband internet worldwide. SpaceX is dedicated to advancing space technology with the goal of enabling human life on other planets. The company was founded in 2002 by Elon Reeve Musk, Kimbal Musk, Michael Kives. Elon Reeve Musk has been the CEO since 2002.

Space Exploration Technologies Corp. - Ordinary Shares - Class A

SpaceX

SpaceX is facing significant downward pressure as investors brace for the first public earnings report and a massive insider lock-up expiration that will flood the market with millions of shares. Community sentiment remains deeply divided between long-term believers citing Starlink growth and aggressive bears betting on a collapse fueled by dilution and valuation concerns.

Luckin Coffee, Inc. engages in providing food and beverage items, and operates coffee retail stores. It has a pioneered a technology-driven retail network to provide coffee and other products of high quality, high convenience and high affordability to customers. The company manages pick-up stores, relax stores, and delivery kitchens. It also offers tea, snacks, and light meals through its mobile application. The company was founded by Zhi Ya Qian, Fei Yang and Jin Yi Guo on June 16, 2017 and is headquartered in Xiamen, China.

Luckin Coffee Inc - ADR

Luckin Coffee is trending as the community debates its recent earnings performance, with a strong focus on store expansion and operational execution versus concerns over same-store sales and net margins. Investors are actively discussing the impact of subsidy-related volatility and the potential for a future relisting on a major U.S. exchange.

Micron Technology, Inc. engages in the provision of innovative memory and storage solutions. It operates through the following segments: Cloud Memory Business Unit (CMBU), Core Data Center Business Unit (CDBU), Mobile and Client Business Unit (MCBU), and Automotive and Embedded Business Unit (AEBU). The CMBU segment focuses on memory solutions for large hyperscale cloud customers and High-Bandwidth Memory for all data center customers. The CDBU segment is involved in memory solutions for mid-tier cloud, enterprise, and OEM data center customers and storage solutions for all data center customers. The MCBU segment focuses on memory and storage solutions for the mobile and client segments. The AEBU segment is involved in memory and storage solutions for the automotive, industrial, and consumer segments. The company was founded by Ward D. Parkinson, Joseph Leon Parkinson, Dennis Wilson, and Doug Pitman on October 5, 1978 and is headquartered in Boise, ID.

Micron Technology Inc.

Micron Technology Inc

Micron Technology is trending as market participants debate whether high-bandwidth memory (HBM) demand creates a permanent structural shift or if the stock remains vulnerable to cyclicality and heightened geopolitical tensions involving Chinese competition. Community discussions are heavily focused on recent volatility linked to institutional liquidations and potential supply chain shifts, with bullish sentiment anchored in strong fundamental AI demand while bears caution against overvaluation.

Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers small molecules, products produced from biological processes called biologics, and chimeric antigen receptor (CAR-T) cell therapies. The company was founded in August 1933 and is headquartered in Princeton, NJ.

Bristol-Myers Squibb Co.

Bristol-Myers Squibb is seeing significant market movement as reports circulate regarding potential merger talks with AstraZeneca, a move that would create one of the largest companies in the pharmaceutical sector. Investors and community members are actively debating the strategic implications for the oncology market, with many focused on the potential synergy of their combined drug pipelines.

AstraZeneca Plc is a global, science-led biopharmaceutical company focused on the discovery, development, and commercialization of prescription medicines. Its portfolio spans oncology, rare diseases, and biopharmaceuticals, including cardiovascular, renal & metabolism, and respiratory & immunology. The company was founded in 1913 and is headquartered in Cambridge, the United Kingdom.

Astrazeneca plc

AstraZeneca PLC

AstraZeneca is experiencing significant market attention following a high-stakes agreement with the Trump administration that secures a three-year tariff exemption in exchange for increased U.S. manufacturing investments and lower drug prices. While investors evaluate this strategic shift alongside ongoing oncology pipeline catalysts, the community is actively debating the stock's long-term valuation impact and potential growth trajectory.

Advanced Micro Devices, Inc. engages in the semiconductor business. Its products include processors, accelerators, graphics, adaptive SoCs, FPGAs, and SOMs, and software, tools, and apps. The firm offers artificial intelligence, industries, workloads, and gaming solutions. The company was founded by W. J. Sanders III on May 1, 1969 and is headquartered in Santa Clara, CA.

Advanced Micro Devices Inc.

Advanced Micro Devices Inc

AMD is rallying as investors look past short-term volatility and sector-wide sell-offs, betting that the company's expanding AI accelerator demand and strong enterprise partnerships will drive sustained growth. The community remains focused on upcoming earnings, with active debate centered on whether recent price action is a fundamental recovery or a temporary technical rebound.

ProShares Trust II - ProShares UltraShort Bloomberg Crude Oil -2x Shares

ProShares UltraShort Bloomberg Crude Oil

The ProShares UltraShort Bloomberg Crude Oil ETF is trending as traders speculate on the impact of ongoing geopolitical tensions and OPEC+ output policies on oil price volatility. Community members are actively debating the mechanics of the leveraged inverse product, including the effects of decay and potential reverse splits, while balancing tactical bets on de-escalation against expectations of continued supply instability.

UiPath, Inc. engages in the development and provision of a software platform to automate business processes. The firm serves the public, healthcare, telecommunication, finance, and banking industries. It also offers accounts payable automation, claims processing automation, contact center automation, and finance and accounting automation. The company was founded by Daniel Dines and Marius Tirca in 2005 and is headquartered in New York, NY.

UiPath Inc - Ordinary Shares - Class A

UiPath Inc

UiPath is trending as the community actively debates whether current share price volatility is a major accumulation opportunity for the long-term agentic AI and enterprise automation narrative or a sign of deeper structural weakness. Investors are closely monitoring the interplay between software sector rotation, recent institutional activity, and the company's path toward sustained profitability.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Wall Street Turning Towards Momentum Narratives

Small-cap healthcare and emerging growth stocks continue to generate investor interest as multiple companies announced significant regulatory, scientific, and strategic developments. $NTHI, $ERNA, $VIVS, $LLY, $VEEE, $SOBR

Ernexa Scores Independent Validation Before High-Stakes Human Cancer Therapy Trials

Ernexa Therapeutics (NASDAQ:ERNA) has taken a notable step toward the clinic after announcing that an independent contract research organization successfully reproduced the preclinical efficacy of its lead cell therapy candidate, ERNA-101, in ovarian cancer models. Independent validation is closely watched in biotechnology because reproducibility can strengthen confidence in experimental findings before human testing begins.

12 Health Care Stocks Moving In Wednesday's Pre-Market Session

Gainers

Ernexa Therapeutics (NASDAQ:ERNA) stock increased by 88.3% to $11.41 during Wednesday's pre-market session. The market value of their outstanding shares is at $7.0 million.
Catheter Precision (AMEX:VTAK)read more...

ERNA Stock Shoots Up 140% in a Month: Here's What You Should Know

Ernexa Therapeutics stock soars 140% in a month as ERNA-101 shows complete tumor clearance and long-term survival in pre-clinical ovarian cancer models.

Chasing the Next Explosive Small-Cap Run

Risk appetite came roaring back and several companies standing out, as market participants rotated heavily into sectors tied to transformative technologies and high-growth macro trends. $TGNT, $QUCY, $AEHL, $TDIC, $WGRX, $ERNA, $SLS, $WHWK

Ernexa Stock Is Jumping Today: What's Going On?

Ernexa Therapeutics Inc (NASDAQ:ERNA) shares are surging Tuesday after an investor segment and renewed focus on ERNA 101 in ovarian cancer.read more...

ERNA Stock Almost Doubled In Value Today – Smashing Rally Leads To 7 Trading Halts 

Equity

Ernexa Therapeutics reported a first-quarter net loss of $5.51 million, narrower than the $8.20 million loss in the previous corresponding period.

Biotech’s Next Wave May Already be in Motion

The biotech and pharma sector is entering one of its most pivotal periods in years, where insider conviction, late-stage clinical wins, and platform technologies are converging to reshape both valuations and patient outcomes. From aggressive insider buying ahead of critical data to blockbuster Phase 3 readouts redefining entire therapeutic categories, the market is signaling that the next cycle of winners may already be taking shape. $NTHI, $ERNA, $LLY, $NVO, $REGN, $MRNA

ERNA Stock Surged 60% Today – Here’s Why Retail Is Buzzing About Ernexa’s Ovarian Cancer Trial Results

Ernexa’s ERNA-101 achieved complete tumor clearance and 100% long-term survival in syngeneic ovarian cancer models.

Ernexa Therapeutics Stock Climbs On Breakthrough Preclinical Data

Ernexa Therapeutics, Inc. (NASDAQ:ERNA) shares are trading higher Wednesday after the company announced preclinical data showing its ERNA-101 cell therapy candidate achieved complete tumor clearance...

This account has been verified as an official ERNA representative.

Verified Account

Ernexa Therapeutics

Ernexa Therapeutics, Inc. engages in the provision of cell engineering therapies. It is involved in the development of mRNA cell engineering technologies to repair cellular dysfunction and treat a range of therapeutic indications. The company was founded in 1984 and is headquartered in Cambridge, MA.

Ernexa Therapeutics Inc.

Bearish Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$3.28
Prev Close	$3.47
Open	$3.43
Dividend Yield	0.00%
50-Day Moving Average	$6.82
Beta	0.85
Avg. Volume	58,586.03
PE Ratio	-0.11

52-Week High	$71.50
52-Week Low	$3.18
Market Capitalization	$3.83M
EPS (Annual)	-$55.89
Price to Book	0.56
Revenue Per Employee	$0.00

Feed

News

Sentiment

Fundamentals

Info